# The DoHAICs Study Expansion Phase

> **NCT07584018** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 90 (estimated)

## Conditions studied

- HCC - Hepatocellular Carcinoma

## Interventions

- **DRUG:** Donafenib
- **DRUG:** sintilimab
- **PROCEDURE:** HAIC

## Key facts

- **NCT ID:** NCT07584018
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-20
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07584018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07584018, "The DoHAICs Study Expansion Phase". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT07584018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*